A-Shine s.r.o.

Plzen 3 39 trials 16 recruiting

39 Registered trials

16 Currently recruiting

Organisation

A-Shine s.r.o.

Location

Plzen 3, Czechia

Identifier

ORG-100044111

Address

Sumavska 2, Vychodni Predmesti, 301 00, Czechia

Departments

A-Shine s.r.o
A-SHINE s.r.o.
A-Shine, s.r.o.
N.A
N/A
NA
Neurologie
Oddeleni psychiatrie
Private practice
Psychiatrická ambulance
Psychiatrie
Psychiatry

Clinical trials at this site (39)

Search interface

A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Treatment-resistant depression 5 2024-02-09
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Cognitive disorder 4 2024-06-13
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o… Ended

2022-500538-27-00 Adjunctive therapy to antidepressants for the treatmen 10 2023-03-30
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in… Ended

2023-510047-37-00 Treatment-resistant depression (TRD) 4 2023-03-30
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5